Compare abrdn Income Credit Strategies Fund (ACP) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Medtronic PLC — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Medtronic PLC trades at $82.06 (market cap $107.31B). The key difference: Medtronic PLC is far larger — about 163.5× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | MDT | |
|---|---|---|
Market Cap | $656.21M | $107.31B |
Sector | Financials | Health |
52-Week High | $5.98 | $105.35 |
52-Week Low | $5.01 | $73.75 |
Dividend Yield | 17.78% | 3.44% |
Enterprise Value | — | $126.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Medtronic (MDT) trades at $83.83, up 0.77% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company shows improving fundamentals with 2025 revenue of $33.54B and net income of $4.66B, supported by a 13.2% net margin. Recent acquisition of Scientia Vascular enhances its neurovascular portfolio, while analyst consensus remains strongly positive with a $98.77 price target.
MDT presents a compelling investment case with steady growth, a 3.5% dividend yield, and undervaluation relative to analyst targets. Key risks include rising debt levels and margin pressures from tariffs. The stock's current position near support levels offers a potential entry point for long-term investors seeking healthcare sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
